Investor Confidence Wavers as Bayer Navigates Legal and Financial Crossroads

Bayer shares consolidate as Q4 operational beat is offset by legal losses. Technical support at €33.60 is critical, with Supreme Court glyphosate ruling a key risk.

Bayer AG's stock continues to face significant headwinds. The company's shares have been consolidating since mid-February, testing crucial support levels, following a mixed fourth-quarter 2025 performance and persistent legal uncertainties. While there are operational bright spots, the overall climate for investors remains one of pronounced caution.

Technical Picture Hangs in the Balance

From a chart analysis perspective, Bayer's equity has been in a consolidation phase. A key support zone is seen around €33.60, which rests just above the 200-day moving average of €31.86. Market technicians suggest that holding this area could pave the way for stabilization. Immediate resistance levels are identified near €39.91 and €41.22. A decisive break below the 200-day line, however, would likely invite further selling pressure. The coming weeks are viewed as pivotal for determining whether the stock establishes a durable base or if the current corrective phase extends.

A Quarter of Contrasting Results

The conglomerate's Q4 2025 results highlighted its ongoing dichotomy. On an operational basis, performance surpassed expectations, with adjusted earnings per share reaching €0.62. Yet, this was overshadowed by a substantial net loss of €3.82 per share, driven by multi-billion euro provisions for ongoing litigation. This compares to a much smaller loss of €0.34 per share in the prior-year period. Group revenue also declined, falling approximately 2.5% year-over-year to €11.44 billion.

Despite these challenges, analyst projections for the full 2026 fiscal year are more optimistic. The consensus forecast anticipates a profit of €4.52 per share, which would represent a significant recovery. Research from MWB points to improved operational visibility that may extend into the coming year.

The Persistent Shadow of Glyphosat

The most substantial overhang for the company remains the legal legacy of its Monsanto acquisition. Analysts at Berenberg highlight a pending decision from the U.S. Supreme Court regarding damages claims linked to the glyphosate-based herbicide. This ruling has the potential to dramatically reshape the market's risk assessment and the group's future liability burden. Until greater clarity emerges from the courts, the share price is expected to remain vulnerable to heightened volatility.

For a sustained reversal in sentiment, market observers agree that Bayer will need to demonstrate tangible operational progress alongside favorable legal developments to rebuild investor trust.